{"entity":{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","aka":[],"tldr":"Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.","summary":"Laurie Sehn developed the revised International Prognostic Index for the rituximab era, led the BC Cancer population-based studies that showed R-CHOP's real-world impact, and was a lead investigator of the GO29365 trial establishing polatuzumab vedotin in relapsed DLBCL and of POLARIX. She authored the 2021 NEJM review of DLBCL and chairs lymphoma care in British Columbia.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehn%20LH%5BAuthor%5D%20diffuse%20large%20B-cell%20lymphoma"}],"tags":["lymphoma","canada","outcomes"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":["adc"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["bc-cancer"],"pathways":[],"terms":[],"trials":["polarix"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Lymphoma Tumour Group, BC Cancer; Clinical Professor, University of British Columbia","institutionId":"bc-cancer","specialisms":["Diffuse large B-cell lymphoma","Population-based outcomes","Novel agents","Prognostic indices"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sehn%20LH%5BAuthor%5D%20diffuse%20large%20B-cell%20lymphoma"}],"papers":[{"title":"Diffuse large B-cell lymphoma","journal":"NEJM","year":2021,"doi":"10.1056/NEJMra2027612"},{"title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.00172"}]},"route":"/people/laurie-sehn/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"institution":[{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/"}],"trial":[{"id":"goya","kind":"trial","name":"GOYA","route":"/trials/goya/"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/"}],"paper":[{"id":"paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","kind":"paper","name":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","route":"/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/"},{"id":"paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","kind":"paper","name":"Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)","route":"/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/"},{"id":"paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","kind":"paper","name":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","route":"/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}